Page last updated: 2024-10-27

fluorouracil and Haim-Monk Syndrome

fluorouracil has been researched along with Haim-Monk Syndrome in 1 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"While the most frequent, surgery for colorectal cancer is avoided in patients with metastases to the regional lymph nodes (stage III) or distant ones (stage IV)."2.76[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer]. ( Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eropkin, PV1
Rybakov, EG1
Kashnikov, VN1
Panina, MV1

Trials

1 trial available for fluorouracil and Haim-Monk Syndrome

ArticleYear
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
    Voprosy onkologii, 2011, Volume: 57, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2011